127 related articles for article (PubMed ID: 38652512)
1. Navigating the complexity of post-NAT therapy in breast cancer: The role of ctDNA testing.
Abahssain H; Souadka A
J Surg Oncol; 2024 Apr; ():. PubMed ID: 38652512
[No Abstract] [Full Text] [Related]
2. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
Front Oncol; 2021; 11():736769. PubMed ID: 34868925
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
Yue D; Liu W; Chen C; Zhang T; Ma Y; Cui L; Gu Y; Bei T; Zhao X; Zhang B; Bai Y; Romero A; Xu-Welliver M; Wang C; Zhang Z; Zhang B
Transl Lung Cancer Res; 2022 Feb; 11(2):263-276. PubMed ID: 35280315
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M
Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692
[TBL] [Abstract][Full Text] [Related]
6. Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study.
Wang XY; Zhang R; Han JH; Chen SQ; Zhao FL; Chen H; Lin J; Fan J; Zhu WW; Lu L; Chen JH
Ann Surg Oncol; 2023 Aug; 30(8):5252-5263. PubMed ID: 37202570
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
medRxiv; 2023 Mar; ():. PubMed ID: 36945501
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer.
Watanabe K; Nakamura T; Kimura Y; Motoya M; Kojima S; Kuraya T; Murakami T; Kaneko T; Shinohara Y; Kitayama Y; Fukuda K; Hatanaka KC; Mitsuhashi T; Pittella-Silva F; Yamaguchi T; Hirano S; Nakamura Y; Low SK
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232820
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
[TBL] [Abstract][Full Text] [Related]
10. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.
Ranghiero A; Frascarelli C; Cursano G; Pescia C; Ivanova M; Vacirca D; Rappa A; Taormina SV; Barberis M; Fusco N; Rocco EG; Venetis K
Cytopathology; 2023 Nov; 34(6):519-529. PubMed ID: 37640801
[TBL] [Abstract][Full Text] [Related]
12. Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study.
Bernardi D; Vatteroni G; Acquaviva A; Valentini M; Sabatino V; Bolengo I; Pellegrini M; Fantò C; Trimboli RM
AJR Am J Roentgenol; 2022 Dec; 219(6):884-894. PubMed ID: 35731101
[No Abstract] [Full Text] [Related]
13. Can Radiologic Tumor Size Following Neoadjuvant Therapy Reliably Guide Tissue Resection in Breast Conserving Surgery in Patients with Invasive Breast Cancer?
Walcott-Sapp S; Srour MK; Lee M; Luu M; Amersi F; Giuliano A; Chung A
Am Surg; 2020 Oct; 86(10):1248-1253. PubMed ID: 33284669
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.
Iams WT; Mackay M; Ben-Shachar R; Drews J; Manghnani K; Hockenberry AJ; Cristofanilli M; Nimeiri H; Guinney J; Benson AB
JAMA Netw Open; 2024 Jan; 7(1):e2351700. PubMed ID: 38252441
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
16. Timing to imaging and surgery after neoadjuvant therapy for breast cancer.
Grubstein A; Rapson Y; Stemmer SM; Allweis T; Wolff-Bar M; Borshtein S; Eden S; Tamir S; Atar E; Sharon E; Shochat T; Yerushalmi R
Clin Imaging; 2021 Mar; 71():24-28. PubMed ID: 33171362
[TBL] [Abstract][Full Text] [Related]
17. Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy.
Ren Z; Pineda FD; Howard FM; Hill E; Szasz T; Safi R; Medved M; Nanda R; Yankeelov TE; Abe H; Karczmar GS
Acad Radiol; 2022 Oct; 29(10):1469-1479. PubMed ID: 35351365
[TBL] [Abstract][Full Text] [Related]
18. The Role of Cell-Free DNA in Cancer Treatment Decision Making.
Telekes A; Horváth A
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551600
[TBL] [Abstract][Full Text] [Related]
19. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D
Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313
[TBL] [Abstract][Full Text] [Related]
20. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
